Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting

Media Release

- 8 abstracts on Genmab programs scheduled for presentation at ASCO
- Two daratumumab oral presentations and five daratumumab poster presentations

Copenhagen, Denmark; April 20, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6. These abstracts, submitted by our collaboration partner, Janssen Biotech, Inc., include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation. In addition, descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of our Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting. The titles of the abstracts are currently available on the ASCO website with the full abstracts scheduled to be published on May 17, 2017.

“We are very pleased that, once again, a number of abstracts based on exciting work with Genmab’s innovative therapeutic antibody products have been accepted for presentation at the prestigious ASCO conference,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

List of abstracts:

**Daratumumab:**
Efficacy Of Daratumumab In Combination with Lenalidomide Plus Dexamethasone (DRd) or Bortezomib Plus Dexamethasone (DVd) in Relapsed or Refractory Multiple Myeloma Based on Cytogenic Risk Status – Oral presentation, Sunday, June 4, 11:45 AM – 11:57 AM CDT

Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma: An Open-Label, Phase Ib Study – Oral presentation, Sunday, June 4, 9:45 AM – 9:57 AM CDT

Safety and Efficacy of Daratumumab-based Regimens in Elderly (≥75 years) Patients with Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of POLLUX and CASTOR – Poster presentation, Monday, June 5, 8:00 AM – 11:30 AM CDT

Daratumumab, Lenalidomide and Dexamethasone (DRd) versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Update (POLLUX) – Poster presentation, Monday, June 5, 8:00 AM – 11:30 AM CDT

Daratumumab, Bortezomib and Dexamethasone (DVd) versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Update (CASTOR) – Poster presentation, Monday, June 5, 8:00 AM – 11:30 AM CDT

Randomized, Open-label Phase Ib/II Study of Atezolizumab with or without Daratumumab in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer – Trials in Progress Poster presentation, Saturday, June 3, 8:00 AM – 11:30 AM CDT

Comparative Efficacy of Multiple Myeloma Therapies for Treatment of First Relapse – A Systematic Literature Review and Network Meta-analysis – Poster presentation, Monday, June 5, 8:00 AM – 11:30 AM CDT
Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting

HuMax-AXL-ADC:
GCT1021-01, a First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to evaluate Safety of Axl-Specific Antibody-Drug Conjugate (HuMax-AXL-ADC) in Patients with Solid Tumors – Trials in Progress Poster presentation, Monday, June 5, 8:00 AM – 11:30 AM CDT

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®, the Y-shaped Genmab logo®, Genmab in combination with the Y-shaped Genmab logo™, the DuoBody logo®, the HexaBody logo™, HuMax®, HuMax-CD20®, DuoBody®, HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.